Inhaled Recombinant Non-immunogenic Staphylokinase vs Placebo in Patients With COVID-19 - FORRIF Trial

NCT05135546 PHASE2, PHASE3 TERMINATED

Objective: to evaluate the tolerability, safety and efficacy of inhaled usage of the Recombinant Non-immunogenic Staphylokinase (Fortelyzin®) vs placebo in patients with COVID-19.

Details

Lead sponsor	Supergene, LLC
Phase	PHASE2, PHASE3
Status	TERMINATED
Enrolment	4
Start date	Mon Dec 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed May 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• COVID-19

Interventions

• Recombinant nonimmunogenic staphylokinase
• Placebo

Countries

Russia